Introduction {#sec1-1}
============

HIV-1 during its replication cycle interacts with the host restrictions factors of which APOBEC3G. The apolipoprotein B mRNA editing-enzyme catalytic polypeptide- like editing complex 3G (APOBEC3G), belongs to the cytidine deaminase family which comprise 10 proteins. ^[@ref1]^ It is a potent inhibitor of HIV-1 replication, and act by deaminating cytidines in uracil on the negative strand of the viral cDNA and the virion infectivity factor Vif of HIV can hinder APOBECG action by targeting it to degradation in the proteasomes.^[@ref2],[@ref3]^ *APOBEC3G* expression has been reported to be elevated in seronegative compared to HIV subtype B and C infected individuals.^[@ref4],[@ref5]^ Although the latter findings were different, when the individuals were infected by circulating recombinant forms of HIV. A gene expression can be reduced by mutations. For this case-control study the aims were to evaluate the level of *APOBEC3G* expression in subjects' naïve to HAART infected by HIV-1 and the effect of *APOBEC3G* polymorphisms on its expression.

Materials and Methods {#sec1-2}
=====================

Study population {#sec2-1}
----------------

All experiments were performed in compliance with relevant laws and institutional guidelines and in accordance with the ethical standards of the Declaration of Helsinki. Approval for the study was obtained from the Ethics Committee for Health Research of Burkina Faso. All study participants or guardians gave their free written and informed consent.

The study group consisted of 38 participants who were newly detected HIV+ naïve to treatment and 40 HIV negative individuals as controls. Both groups were recruited from the Saint Camille Hospital and the Pietro Annigoni Biomolecular Research Center (CERBA) cohorts and outpatients. Blood samples obtained by venipuncture were tested for HIV infection, using alere determine HIV-1/2 test, and the SD Bioline HIV1/2 test was used to differentiate between HIV-1 and HIV-2. CD4 cells were enumerated using the BD FACSCount CD4 Reagent kit on a BD FACS COUNT (Becton Dickinson, San Jose). Viral load was determined using the Abbott HIV-1 Real Time Quantitative kit (Promega, USA) on the Abbott m2000rt (Abbot Laboratories, Illinois) according to the manufacturer's protocol.

DNA extraction and APOBEC3G expression {#sec2-2}
--------------------------------------

Genomic DNA was extracted from leucocytes using the *DNA Rapid Salting-Out* technique as described by Miller *et al*.^[@ref6]^ APOBEC3G variants, rs8177832 (H186R), rs35228531 and rs6001417 were genotyped as previously described.^[@ref7]^

Total RNA was extracted from frozen Plasma using the purelink pro kit (Invitrogen).

*APOBEC3G* mRNA expression was quantified in 38 HIV positive subjects and in 40 HIV negative subjects. Amplification of APOBEC3G was performed using a reverse transcription and target specific primers which are respectively: 5'-GCGGCCTTCAAGGAAACC- 3', forward: 5'- CTGCTGAACCAGCGCAGG-3' reverse: 5'-GCGGCCTTCAAGGAAACC-3' and probe: 5'-CTTTCTATGCAACCAGGCTCCACATAAAC- 3'. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a housekeeping gene to normalize for differences in cell counts or differences in RNA extraction.

Each 20 μL optimized PCR reaction mix contained: 10 μL of Express superscript Qpcr SuperMix Universal, 2 μL of each 50 μM primer, or GAPDH, 3 μL of probe mix (10 pmol/μL), 0.04 μL of ROX reference Dye, 2 μL of EXPRESS SUPERSCRIPT MIX for One step qPCR and 5 μL of RNA. The TaqMan quantitative real time RT-PCR was performed using the Applied Biosystems Prism 7500 Sequence Detection System, (Foster City, CA) according to the following Cycling conditions: 1 cycle at 50˚C for 15minute hold (cDNA synthesis), 1 cycle at 92˚C for 20 seconds and 45 cycles of 92˚C for 15 seconds and 60˚C for 1 minute. Values are expressed as calculated as fold change using the delta-Ct method.

Statistical analysis {#sec2-3}
--------------------

The software SPSS version 20.0 and GRAPHPAD were used for data analysis. Power-Marker software Version 3.25 was used for the determination of the Hardy- Weinberg equilibrium and the calculation of allele and genotype frequencies. Differences between the groups were assessed using the Mann-Whitney U test for non-parametric analyses. Any value was considered statistically significant for P\<0.05.

Ethical consideration {#sec2-4}
---------------------

Approval for the study was obtained from the National Ethics Committee for Health Research of Burkina Faso. (Deliberation No. 2014-7-086). All study participants or guardians gave their free written and informed consent according to the Helsinki Declarations.

Results {#sec1-3}
=======

Differences in mRNA expression {#sec2-5}
------------------------------

*APOBEC3G* mRNA was analyzed for all subjects in the study by Real-time qPCR. Higher expression levels of *APOBEC3G* were observed in HIV positive-untreated compared to controls (HIV-1 seronegative) but the difference was not significant (P=0.5457).

Among HIV positive participants, *APOBEC3G* expression level was higher in those with a CD4 count over 500 compared to the participants having a T CD4 counts less 500. This difference was significant (P=0.0411).

When comparing the mRNA expression among HIV positive individuals who had a viral load over 5000 copies/ml and those who had a viral load lower than 5000; the ladder had a higher expression of *APOBEC3G*. This difference was not statistically significant.

In this study, the population of interest was genotyped for 3 *APOBEC3G* polymorphisms rs6001417, rs8177832 and rs3522835. The expression level of *APOBEC3G* was compared among HIV positive and HIV negative participants, in relation to their different genotypes ([Figures 1](#fig001){ref-type="fig"} and [2](#fig002){ref-type="fig"}). For rs6001417, *APOBEC3G* expression level seems to be higher in HIV positive carriers of G alleles compared to controls, but the difference was not significant. When comparing APOBEC3G expression in relations to the genotypes of rs8177832 in cases and controls; the carriers of the G alleles also had a higher expression of *APOBEC3G* mRNA (P=0.0469). For rs352283, the carriers of the T allele in the HIV positive group have roughly a high expression level of *APOBEC3G* mRNA compared to HIV negative carrier of the T allele.

Discussion {#sec1-4}
==========

In this study, the investigation was whether the expression level of *APOBEC3G* would be higher in the seronegative participants (control group) compared to the HIV positive participants. The results show that the *APOBEC3G* expression level is higher in the HIV positive group compared to the control group, which implies that *APOBEC3G* expression levels are upregulated upon HIV-1 infection. Although this finding is very different from many studies which found that *APOBEC3G* expression level was downregulated upon HIV-1 infection^[@ref4],[@ref5],[@ref8],[@ref9]^; these results are similar to that of studies with samples from Senegal,^[@ref10],[@ref11]^ and could be explained by the fact that in both Senegal and Burkina Faso located in West Africa where HIV-1 CRFs are predominant.^[@ref12]^

When correlating the CD4 T count and the viral load to APOBEC3G expression level among HIV positive participants; individuals with a high CD4 count had a higher expression of *APOBEC3G* than the individuals with a low CD4 count, while participants with a low viral load seem to have a higher *APOBEC3G* expression level compared to the ones that have a high viral load. These results could be explained by the fact, that individuals with a high CD4 count express more *APOBEC3G* and thus control HIV replication thus a low viral load.^[@ref11]^

The *APOBEC3G* mRNA expression in relations to the genotypes of rs8177832 in cases and controls shows that the HIV-1 infected carriers of the G minor alleles had a higher expression of *APOBEC3G* mRNA than the controls on the coding exon 4 and that a nucleotide change could modulate the expression of the putative gene. This study has some limits that are due on one hand by the small sample size and on the other hand by the limited number of the tested mutations which could influence *APOBEC3G* expression among the seropositive and seronegative patients.

In fact, different mutations have been associated either with the augmentation or the reduction of *APOBEC3G* gene and localized on the gene promoter have not been studied in the present work.^[@ref15]^

In conclusion, this study supports previous findings on samples from West Africa that *APOBEC3G* expression level is higher in the HIV positive group compared to the control group, and that individuals with a high CD4 count had a higher expression of *APOBEC3G* than the individuals with a low CD4 count, while participants with a low viral load seem to have a higher *APOBEC3G* expression level compared to the ones with a high viral load.

Conclusions {#sec1-5}
===========

The highlight of the study is that the HIV-1 infected carriers of the G minor alleles of the variant rs8177832 had a higher expression of *APOBEC3G* mRNA than the controls carriers of the G minor allele. Further investigations are needed to understand if the differences are due to HIV-1 subtypes or populations genetic variations.
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